A decision by the Centers for Medicare & Medicaid Services to require coverage with evidence development for beta amyloid imaging agents means that Medicare patients will probably have to wait at least a few more years to receive Eli Lilly and Co.'s marketed Amyvid florbetapir outside a clinical trial.

On Sept. 27, CMS issued a final decision to limit reimbursement of beta amyloid imaging to one scan per Medicare patient with dementia or neurodegenerative diseases enrolled in clinical trials under its coverage with evidence development (CED) policy.